Cardiovascular

Featured Article
Poor Depression Care After Heart Attack, Stroke Increases Patient Costs
Study findings show that 60% of patients receive inadequate care for major depressive disorder following heart attack or stroke, which researchers say is linked with notably higher health care costs.
Antihypertensives: Which Treatment Option Is Most Effective?
In a recent study, researchers compared effectiveness and safety of antihypertensive drugs and outcomes from observational data from 4.9 million patients.
Statins Are Underprescribed, Prescribed at Lower Intensities in Patients With HIV
“This study reveals that [people living with HIV] may be at a substantial disadvantage in terms of receiving correct statin therapy for ASCVD risk reduction,” the researchers concluded.

Newsfeed

Poor Depression Care After Heart Attack, Stroke Increases Patient Costs
Antihypertensives: Which Treatment Option Is Most Effective?
Statins Are Underprescribed, Prescribed at Lower Intensities in Patients With HIV
Blood Pressure Variability Linked to Alzheimer’s Disease Progression
Amgen Sets One Lower List Price for its Cholesterol Drug
Sanofi Pulls Zantac From U.S. and Canada After Carcinogen Found
Gender-Specific Hypertension Guidelines Are Needed to Improve Stroke Prevention
Cardiovascular Events More Prevalent in Patients Denied PCSK9 Inhibitor Coverage
View More

Insights

Ranolazine-Angiotensin Inhibitor Interactions: Reality or Fantasy?
Mark Munger, PharmD, discusses recent study findings, which show that ranolazine increases the adverse effect profile of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, raising concern for patient safety.
How Vitamin D Supplementation, Cardiovascular Disease Risk Relate
Mahmoud Barbarawi, MD, department of internal medicine at the Hurley Medical Center (Flint, Michigan), shares insights from his recent study and highlights gaps of knowledge that still exist between vitamin D supplementation and cardiovascular…
Improving Multiple Outcomes With One Treatment
Kiersten Combs, vice president of US Cardiovascular & Metabolic Disease, and Jim McDermott, vice president of US Medical Affairs and Metabolism, both at AstraZeneca, highlight how the use of Farxiga and other SGLT2 inhibitors impact payers and…
NSAIDs Plus Aspirin Associated With Development of Incident Heart Failure Risk
Mark Munger, PharmD, explains why there is a critical need to develop a treatment to reduce the incidence of NSAID-induced cardiovascular adverse events, especially heart failure.
View More
Back to Top